Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Stock Hits QuantWave's Price Target with 19.45% Profit

February 01, 2024
ELI LILLY AND COMPANY stock recently reached the price target forecasted by QuantWave, resulting in a profit of 19.45%. The forecast signal date was October 31, 2023, with the price at $547.26 and a predicted long direction. On February 1, 2024, the stock reached the target price of $653.68, achieving the forecasted outcome.

This success can be attributed to various factors, including strong financial performance, positive industry trends, and overall market sentiment. ELI LILLY AND COMPANY's innovative products, strategic partnerships, and robust pipeline have likely contributed to the stock's movement in line with QuantWave's forecast.

QuantWave's achievement of this price target for ELI LILLY AND COMPANY showcases the platform's accuracy and reliability in predicting stock movements. Investors and traders can benefit from accessing QuantWave's forecasts for a wide range of stocks, offering opportunities for potential profits. For those interested in learning more about QuantWave's investment strategy, exploring QuantSchool's educational resources is highly recommended. QuantSchool provides a comprehensive professional investment framework, revealing key principles for generating consistent income using the QuantWave forecasting system.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYAugust 12, 2025Eli Lilly and Co LLY Traded Lower in Q2 Despite Good Results  ~1 min.

Eli Lilly and Company, despite reporting good results in the second quarter of this year, saw its stock price traded lower....


LLYAugust 1, 2025Eli Lilly and Company Completes Acquisition of Verve Therapeutics, Advancing One-Time Treatments for High Cardiovascular Risk  ~1 min.

Eli Lilly and Company has announced the successful completion of its acquisition of Verve Therapeutics, a move that will help advance innovative one-time treatments for individuals with high cardiovascular risk. This strategic decision showcases the company's commitment to revolutionizing the healthcare industry and improving patient outcomes. Investors are eagerly watching as Eli Lilly continues ...


LLYJuly 20, 2025Strong Q2 Forecast for ELI LILLY AND COMPANY by J.P. Morgan  ~1 min.

According to J.P. Morgan, Eli Lilly and Company is expected to have a strong second quarter performance. The pharmaceutical giant has been receiving positive attention from investors and analysts alike....


LLYMarch 22, 2025Eli Lilly and Company LLY: Leading the Way in Pharmaceutical Innovation  ~2 min.

Eli Lilly and Company (LLY) continues to make waves in the pharmaceutical industry with its innovative and groundbreaking therapies....


LLYMarch 19, 2025Eli Lilly and Company LLY Surges After Breakthrough BRAVE-AA-PEDS Study Results  ~2 min.

Eli Lilly and Company (LLY) has recently made a significant breakthrough in its BRAVE-AA-PEDS study, resulting in a surge of investor attention and market gains....


LLYMarch 18, 2025Eli Lilly and Company: A Promising Investment in the Pharma Industry  ~1 min.

Eli Lilly and Company (LLY) has been making waves in the pharmaceutical industry with its innovative products and strong performance....


LLYMarch 17, 2025Eli Lilly and Company's Groundbreaking Discovery Revolutionizes Pharma Industry  ~2 min.

Eli Lilly and Company, a renowned pharmaceutical giant, has recently made a groundbreaking discovery that is set to revolutionize the entire industry....


LLYMarch 16, 2025Is Eli Lilly and Company LLY Set to Revolutionize the Pharma Industry?  ~2 min.

Eli Lilly and Company (LLY) has been making headlines recently with its groundbreaking research and innovative products....


LLYMarch 14, 2025Eli Lilly and Company Reports Promising Results in Hair Regrowth Study  ~1 min.

Eli Lilly and Company (LLY) recently announced the positive outcome of their Phase 3 clinical trial for baricitinib, a drug aimed at treating severe alopecia areata in adolescents....


LLYFebruary 28, 2025Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding 50 billion  ~1 min.

Eli Lilly and Company (LLY) is set to significantly increase its manufacturing investment in the United States, surpassing a staggering 50 billion since 2020....


CHTMay 2, 2025CHUNGHWA TELECOM CO., LTD. Hits Price Target Forecast with 6.37% Profit  ~1 min.

QuantWave's forecast for CHUNGHWA TELECOM CO., LTD. proved to be highly accurate as the stock reached the predicted target price on May 2, 2025....


GMOctober 22, 2024GENERAL MOTORS COMPANY Stock Hits Price Target Forecast with 20.31% Profit - QuantWave Analysis  ~1 min.

GENERAL MOTORS COMPANY stock successfully achieved the price target forecast as predicted by QuantWave, resulting in a profit of 20.31%....


AMGNSeptember 20, 2023AMGEN INC. Hits Price Target Forecast with 16.3% Profit, QuantWave's Success in Analytics Showcased  ~1 min.

AMGEN INC. has successfully reached the price target forecast set by QuantWave with a profit of 16.3%. The forecast signal was issued on July 25, 2023, at a price of 221.05 $....


NVDAFebruary 22, 2024QuantWave Hits Target Forecast for NVIDIA CORPORATION with 80.48% Profit  ~1 min.

On September 19, 2023, QuantWave issued a long forecast signal for NVIDIA CORPORATION when the stock was trading at $43.5....


TEFMay 27, 2025TELEFÓNICA, S.A. Hits Price Target with 19.86% Profit: QuantWave Forecast Success  ~1 min.

Telefónica, S.A. stock achieved the forecasted price target as predicted by QuantWave, resulting in a profitable return of 19.86%. ...